Insider Transactions in Q3 2021 at Intellia Therapeutics, Inc. (NTLA)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 24
2021
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,923
+47.62%
|
$95,076
$12.62 P/Share
|
|
Sep 21
2021
|
David Lebwohl EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,400
-75.21%
|
$357,600
$149.81 P/Share
|
|
Sep 21
2021
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,400
+42.93%
|
$28,800
$12.62 P/Share
|
|
Sep 07
2021
|
Glenn Goddard EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,482
-100.0%
|
$626,760
$180.12 P/Share
|
|
Sep 07
2021
|
Glenn Goddard EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,482
+50.0%
|
$48,748
$14.58 P/Share
|
|
Sep 01
2021
|
John M Leonard President and CEO |
SELL
Open market or private sale
|
Direct |
44,735
-5.86%
|
$7,604,950
$170.0 P/Share
|
|
Sep 01
2021
|
John M Leonard President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
44,735
+2.88%
|
$894,700
$20.88 P/Share
|
|
Aug 31
2021
|
Glenn Goddard EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
24,800
-100.0%
|
$3,968,000
$160.22 P/Share
|
|
Aug 31
2021
|
Glenn Goddard EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,800
+28.41%
|
$396,800
$16.93 P/Share
|
|
Aug 31
2021
|
John M Leonard President and CEO |
SELL
Open market or private sale
|
Direct |
37,833
-5.0%
|
$5,864,115
$155.0 P/Share
|
|
Aug 31
2021
|
John M Leonard President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
37,833
+4.76%
|
$529,662
$14.58 P/Share
|
|
Aug 30
2021
|
Glenn Goddard EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,200
-40.58%
|
$811,200
$156.88 P/Share
|
|
Aug 30
2021
|
Glenn Goddard EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,200
+50.0%
|
$98,800
$19.27 P/Share
|
|
Aug 30
2021
|
David Lebwohl EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,400
-22.08%
|
$376,800
$157.8 P/Share
|
|
Aug 30
2021
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,400
+42.93%
|
$28,800
$12.62 P/Share
|
|
Aug 30
2021
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
97,000
-32.43%
|
$15,132,000
$156.7 P/Share
|
|
Aug 30
2021
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
97,000
+44.6%
|
$1,261,000
$13.83 P/Share
|
|
Aug 30
2021
|
John M Leonard President and CEO |
SELL
Open market or private sale
|
Direct |
38,804
-0.58%
|
$6,053,424
$156.86 P/Share
|
|
Aug 30
2021
|
John M Leonard President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
38,804
+2.51%
|
$504,452
$13.99 P/Share
|
|
Aug 23
2021
|
John M Leonard President and CEO |
SELL
Open market or private sale
|
Direct |
27,139
-1.22%
|
$4,125,128
$152.71 P/Share
|
|
Aug 23
2021
|
John M Leonard President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,139
+3.51%
|
$352,807
$13.4 P/Share
|
|
Aug 19
2021
|
John M Leonard President and CEO |
SELL
Open market or private sale
|
Direct |
22,682
-1.03%
|
$3,424,982
$151.44 P/Share
|
|
Aug 19
2021
|
John M Leonard President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,682
+2.97%
|
$294,866
$13.4 P/Share
|
|
Aug 09
2021
|
David Lebwohl EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,400
-75.21%
|
$393,600
$164.05 P/Share
|
|
Aug 09
2021
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,400
+42.93%
|
$28,800
$12.62 P/Share
|
|
Aug 05
2021
|
Glenn Goddard EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
20,000
-81.42%
|
$3,020,000
$151.4 P/Share
|
|
Aug 05
2021
|
Glenn Goddard EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+50.0%
|
$380,000
$19.27 P/Share
|
|
Aug 04
2021
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
26,000
-27.22%
|
$3,588,000
$138.71 P/Share
|
|
Aug 04
2021
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
26,000
+47.8%
|
$338,000
$13.4 P/Share
|